BMC Cancer最新文献

{"title":"The MAP kinase negative regulator DUSP2 (dual specificity phosphatase 2) is controlled by oncogenic microRNA cluster miR-17-92, miR-106a-363 and miR-106b-25.","authors":"Victoria Tenhaken, Ole-Morten Seternes, Ingolf Cascorbi, Henrike Bruckmueller","doi":"10.1186/s12885-025-14434-z","DOIUrl":"10.1186/s12885-025-14434-z","url":null,"abstract":"<p><strong>Background: </strong>Aberrant changes in protein phosphorylation are a hallmark of cancer, often leading to hyperactivation of signalling pathways such as the mitogen activated protein kinase (MAPK) pathway. Although kinase inhibitors are successfully used in certain clinical indications, drug resistance remains a challenge, and alternative approaches to control phosphorylation-dependent oncogenic signalling are increasingly being considered. These include the modulation of negative regulators of oncogenic signalling pathways. The dual-specificity phosphatase 2 (DUSP2) is one of the essential negative regulators for the MAPK pathway, providing tight and efficient control of MAPKs under physiological conditions. However, in oncogenic contexts, negative feedback regulation is often impaired and the mechanisms controlling DUSP2 expression and function remain largely elusive. The aim of the present study was to investigate whether microRNA-mediated regulation of DUSP2 could contribute to an impairment of negative feedback regulation in cancer.</p><p><strong>Methods: </strong>A combination of in silico target prediction, integrative analysis of pan-cancer microRNA and DUSP2 mRNA expression data as well as a literature search was applied to identify microRNAs potentially regulating DUSP2 expression in cancer context. Predicted interactions of microRNAs with the DUSP2 3'UTR were verified using reporter gene assays and functionally validated in a lymphoma cell model.</p><p><strong>Results: </strong>A comprehensive analysis of microRNA and DUSP2 mRNA expression data across 32 cancer types revealed significant inverse correlations between oncogenic microRNA clusters (miR-17-92, miR-106a-363, and miR-106b-25 cluster) and DUSP2 expression in various cancer types. Reporter gene assay analysis confirmed the interaction of miR-17-5p, miR-20a-5p, miR-20b-5p, miR-29b-3p, miR-93-5p, miR-106b-5p, miR-122-5p, miR-340-5p, miR-520a-3p, and miR-520c-3p with the DUSP2 mRNA 3'UTR. Furthermore, treatment of the lymphoma cell line WSU-DLCL2 with microRNA inhibitors for miR-17-5p, miR-20b-5p, or miR-106b-5p resulted in increased DUSP2 mRNA levels.</p><p><strong>Conclusion: </strong>The results of this study indicate that microRNA-mediated regulation of DUSP2 in hematologic and solid cancers appears to be a plausible mechanism that contributes to the dysregulation of MAP kinase signaling pathways in cancer by impairing negative feedback regulation. The data provide a solid foundation for future studies to investigate the consequences of regulation of DUSP function in cancer in more depth.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1020"},"PeriodicalIF":3.4,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amniotic membrane promotes doxorubicin potency by suppressing SH-SY5Y neuroblastoma cell angiogenesis.","authors":"Ahmed M Abou-Shanab, Shaimaa Shouman, Alaa E Hussein, Ola A Gaser, Shireen Magdy, Eman Ashraf, Radwa Ayman Salah, Omaima Idris, Nagwa El-Badri","doi":"10.1186/s12885-025-14442-z","DOIUrl":"10.1186/s12885-025-14442-z","url":null,"abstract":"<p><strong>Background: </strong>Doxorubicin (DOX) remains a mainstay for neuroblastoma (NB) treatment, but side effects hamper efficacy. We previously showed that DOX induces SH-SY5Y NB cell angiogenesis via the PHD-2/HIF-1α axis. Adjuvant therapies offer a promising avenue to improved outcomes. Human amniotic membrane (hAM) extract (hAME) consists of various proteins that exhibit anti-cancer and anti-angiogenic properties. This study investigates hAME as a potential adjuvant for targeting NB angiogenesis when combined with DOX.</p><p><strong>Methods: </strong>We used cellular, molecular, and biochemical assays to evaluate the antitumorigenic activities of hAME + DOX (D + E) treatment across key hallmarks of SH-SY5Y NB progression: proliferation, cell cycle, angiogenesis, invasiveness, differentiation, and cellular bioenergetics.</p><p><strong>Results: </strong>D + E treatment significantly suppressed SH-SY5Y cell proliferation, induced cell cycle perturbations, and reduced viability, while protecting bone marrow stem cells and human skin fibroblast normal cells. D + E treatment also countered SH-SY5Y cell invasiveness and promoted a favorable mesenchymal-to-epithelial transition (MET). Importantly, D + E treatment modulated the SH-SY5Y cellular respiration, evidenced by halted glycolytic metabolism, potentially influencing a shift towards oxidative phosphorylation and boosted urea cycle progression. Mechanistically, D + E abrogated DOX's pro-angiogenic effects and inhibited SH-SY5Y cells' neo-vascularization in a chick embryo model.</p><p><strong>Conclusions: </strong>These findings suggest hAME as a promising adjuvant therapy for NB, potentially offering an effective and safe treatment strategy by targeting multiple hallmarks of NB.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1021"},"PeriodicalIF":3.4,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.","authors":"Haiyan Chen, Yaner Yu, Shuangqiu Zhu, Jian Zhao, Yan Ma, Zhifei Huang, Hao Jiang, Qichun Wei","doi":"10.1186/s12885-025-14439-8","DOIUrl":"10.1186/s12885-025-14439-8","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1019"},"PeriodicalIF":3.4,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Detecting radiation esophagitis using ¹⁸F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapy.","authors":"Xinying Hu, Chao Han, Mingquan Zhang, Jing Jia, Zhengshuai Mu, Zheng Fu, Kailin Qiao, Jinming Yu, Yuchun Wei","doi":"10.1186/s12885-025-14456-7","DOIUrl":"10.1186/s12885-025-14456-7","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1018"},"PeriodicalIF":3.4,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12153149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The bile duct and liver cancer: ON-treatment surveillance of tumor evolution and response to systemic treatment (BILLIONSTARS) study.","authors":"Philip Falk, Sofie Olsson Hau, Hedda Jacobsen, Jakob Eberhard, Caroline Williamsson, Karin Jirström","doi":"10.1186/s12885-025-14429-w","DOIUrl":"10.1186/s12885-025-14429-w","url":null,"abstract":"<p><strong>Background: </strong>Malignancies of the liver and bile ducts are associated with high recurrence rates after surgery and poor prognosis when disseminated. Medical treatment has been improved in recent years, with chemotherapy, targeted therapy and checkpoint inhibitors offering opportunities to influence the course of the diseases. Many patients do not benefit from treatment, however, and predictive and prognostic markers are lacking. The BILe duct and LIver cancer: ON-treatment Surveillance of Tumor evolution And Response to Systemic treatment (BILLIONSTARS) study aims to map how molecular tumor characteristics and pathways of genetic evolution align with treatment response trajectories.</p><p><strong>Methods: </strong>The BILLIONSTARS study is a prospective, single arm observational study. Patients at Skåne University Hospital in Malmö/Lund and Central Hospital in Kristianstad diagnosed with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) who are to be recommended locoregional intervention by surgery, ablation, transarterial chemoembolization or selective internal radiation therapy and/or antitumoral medical treatment will be included. Tissue obtained in the clinical setting through surgery or biopsy along with tissue from research autopsies will be evaluated with targeted deep sequencing. Circulating tumor DNA (ctDNA) and other relevant biomarkers will be analyzed in blood samples obtained at different timepoints, depending on the type of treatment; before surgery or the start of systemic treatment, prior to each course of systemic treatment, if applicable, and at end of treatment.</p><p><strong>Discussion: </strong>The treatment field for HCC and CCC is evolving, thus improving outcomes for patients in the palliative setting. The efficacy of targeted therapy and checkpoint inhibition is however highly variable, and no predictive biomarkers have yet been established. The clinical course of the diseases is also highly variable and unpredictable. With this study, we hope to gain an increased insight into the various biological characteristics of these tumors, including novel potential treatment targets, as well as their spatial and temporal heterogeneity. By conducting research autopsies with comprehensive post-mortem sampling, we expect to further expand our understanding of the molecular events leading to terminal disease. The ultimate goal is to design better individualized and adaptive treatment strategies, thereby improving the outlook for patients with HCC or CCC.</p><p><strong>Trial registration: </strong>This study has been registered in clinicaltrials.gov as NCT06877637 Protocol version 1 March 2025.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1017"},"PeriodicalIF":3.4,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12153108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related quality of life is a significant prognostic factor for recurrence and overall survival in patients with colon cancer.","authors":"Catarina Tiselius, Fanny Johansen, Andreas Rosenblad, Kenneth Smedh","doi":"10.1186/s12885-025-14254-1","DOIUrl":"10.1186/s12885-025-14254-1","url":null,"abstract":"<p><strong>Background: </strong>Health-related quality of life (HRQoL) is associated with survival in patients with cancer; however, there are few studies on the risk of cancer recurrence. We investigated whether HRQoL can predict disease-free and overall survival (DFS/OS) in patients with non-metastatic colon cancer.</p><p><strong>Methods: </strong>This population-based prospective study investigated patients diagnosed with colon cancer between 2012 and 2016. The 30-item European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) was used to measure HRQoL at diagnosis. Cox proportional hazard regression analyses were used to analyse the association between QLQ-C30 scores and DFS/OS.</p><p><strong>Results: </strong>Of the 323 patients with non-metastatic colorectal cancer, n = 41 (12.7%) were diagnosed with recurrence during mean (standard deviation) DFS and OS follow-up times of 5.9 (2.9) and 6.2 (2.7) years, respectively. Cox regression analysis of HRQoL, adjusted for important clinical and demographic variables, showed that a higher global health status was significantly associated with an improved DFS (hazard ratio [HR] 0.86 per 10 points; 95% confidence interval [CI] 0.79-0.94; P < 0.001) as well as OS (HR 0.88 per 10 points; 99% CI 0.80-0.96; P = 0.003).</p><p><strong>Conclusions: </strong>These results demonstrate that HRQoL can predict both DFS and OS in patients with non-metastatic colon cancer. HRQoL should be considered an additional tool in non-metastatic cancer for assessing patients at risk of metastatic disease.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov (NCT03910894).</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1016"},"PeriodicalIF":3.4,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early radiotherapy improved survival of patients with extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy.","authors":"Yunfeng Wang, Xi Su, Jingyi Jia, Tongfang Zhou, Yifei Lu, Lei Zhao, Zhangru Yang, Xiaolong Fu, Ya Zeng, Xuwei Cai","doi":"10.1186/s12885-025-14417-0","DOIUrl":"10.1186/s12885-025-14417-0","url":null,"abstract":"<p><strong>Background and purpose: </strong>This real-world study aimed to investigate the efficacy of early radiotherapy (RT) in ES-SCLC patients treated with first-line chemo-immunotherapy.</p><p><strong>Materials and methods: </strong>ES-SCLC patients were enrolled from August 2018 to October 2023. Patients who received early radiotherapy before disease progression were defined as Early RT group, while the others, named Salvage and Non-RT (S&N RT) group. Propensity score matching (PSM) with a 1:1 ratio was performed to balance the baseline characteristics.</p><p><strong>Results: </strong>In this study, 375 patients with ES-SCLC treated with first-line chemo-immunotherapy were enrolled. The median PFS was 11.4 months of the Early RT group compared to 6.1 months of the S&N RT group (HR = 0.59, 95%CI 0.45-0.77; p < 0.001). The median OS was 23.8 months of the Early RT group versus 18.0 months of the S&N RT group (HR = 0.50, 95%CI 0.34-0.73; p = 0.004). The survival benefit persisted in the PSM cohort. Furthermore, survival was significantly improved in Early RT group compared to Salvage RT group (p = 0.028), while Salvage RT group had a similar survival with Non-RT group (p = 0.868). The risk of adverse events was tolerable. The multivariate analysis also demonstrated that early radiotherapy was an independently positive predictor for PFS and OS.</p><p><strong>Conclusions: </strong>Administering early radiotherapy significantly improved both PFS and OS in patients with ES-SCLC treated with first-line chemo-immunotherapy with tolerable adverse events, while salvage radiotherapy did not improve survival. This finding warrants further validation through prospective randomized studies.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1012"},"PeriodicalIF":3.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk-reducing salpingectomy: considerations from an OBGYN perspective.","authors":"Alexandra Lukey, A Fuchsia Howard, Alice J Mei, Michael R Law, David Huntsman, Celeste Leigh Pearce, Rafael Meza, Gillian E Hanley","doi":"10.1186/s12885-025-14384-6","DOIUrl":"10.1186/s12885-025-14384-6","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1011"},"PeriodicalIF":3.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the global burden of disease study 2021.","authors":"Weigang Wang, Yangle Sun, Jinbo Li, Hongjing Bai, Chaomin Ren, Yongliang Feng, Suping Wang","doi":"10.1186/s12885-025-14416-1","DOIUrl":"10.1186/s12885-025-14416-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;The issue of breast cancer in young women (BCYW) has gained increasing attention over the past few decades. However, a notable gap exists in the literature concerning the comparison of the disease burden of BCYW with that of other age groups. This study presents a comprehensive analysis of the disparities in global, regional, and national burden between BCYW and their middle-aged and elderly counterparts.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The breast cancer data in this study were collected from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD 2021). The age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), age-standardized prevalence rate (ASPR), and age-standardized disability-adjusted life years rate (ASDR), and the Average Annual Percent Change (AAPC) were employed to assess the disease burden of BCYW. The Bayesian Age-Period-Cohort model was used to forecast disease burden from 2022 to 2030.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The AAPC of ASIR of BCYW from 1990 to 2021 was 0.91 (95% CI: 0.77 to 1.05), exceeding the global average (0.49, 95% CI: 0.40 to 0.58) as well as both middle-aged (0.60, 95% CI: 0.47 to 0.73) and elderly groups (0.30, 95% CI: 0.21 to 0.39). The AAPC for ASMR of BCYW experienced a marginal increase of 0.02 (95%CI: -0.07 to 0.11) from 1990 to 2021, surpassing the rates observed in both the middle-aged group (-0.40, 95%CI: -0.47 to -0.32) and the elderly group (-0.50, 95%CI: -0.62 to -0.38). The ASIR in BCYW significantly increased in regions with low (AAPC = 1.87), low-middle (AAPC = 2.32), middle (AAPC = 1.84), and high-middle SDI (AAPC = 0.98), while it remained unchanged in regions with high SDI (AAPC = -0.02). This trend was also observed among middle-aged and older groups. The ASMR in BCYW significantly increased in regions with low (AAPC = 1.01) and low-middle SDI (AAPC = 1.25), but remained unchanged in regions with middle SDI (AAPC = 0.02), while it decreased in regions with high-middle (AAPC = -1.10) and high SDI (AAPC = -1.60). Among the middle-aged and elderly populations, there was an increase in ASMR rates observed in regions with low, low-middle, and middle SDI groups (all AAPC &gt; 0), whereas a decrease was noted in the regions with high-middle and high SDI (all AAPC &lt; 0). The BAPC predicts a consistent annual increase in ASIR, ASMR, ASPR, and ASDR of BCYW globally and in China from 2022 to 2030. Notably, China has higher ASIR and ASPR rates compared to the global average, while its ASMR and ASDR rates are lower.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The burden of BCYW was particularly significant in regions with low-SDI, low-middle SDI, and middle SDI. Despite the progress made, China still faces considerable challenges in effectively addressing this issue. The prevention and control of BCYW must remain a priority. Different countries and regions should develop personalized, targeted intervention strategies for this population and establish pu","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1015"},"PeriodicalIF":3.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis.","authors":"Yuxi Ma, Yuting Li, Zhenyu Lin, Jing Wang, Jianli Hu, Hongli Liu, Yali Yang, Junli Liu, Tao Zhang","doi":"10.1186/s12885-025-14206-9","DOIUrl":"10.1186/s12885-025-14206-9","url":null,"abstract":"<p><strong>Background: </strong>For gastric cancer patients, peritoneal metastasis poses a life-threatening risk due to the high incidence of treatment failure and disease recurrence. Conducting additional research aimed at identifying more efficacious strategies is imperative for enhancing treatment outcomes. This study examined the efficacy and safety of systemic chemotherapy plus a PD-1 inhibitor combination with intravenous or intraperitoneal bevacizumab for gastric cancer with peritoneal metastasis.</p><p><strong>Methods: </strong>We conducted the open label, two-arm pilot study involved receiving albumin-bound paclitaxel (260 mg/m², d1) plus S-1 (80 mg/m², d1-14) combined with sintilimab (200 mg, d1) and bevacizumab (7.5 mg/m², d1) (Arm A) intraperitoneally for moderate or large ascites or intravenously (Arm B) for non- or small ascites. The clinical trial was registered at the Chinese Clinical Trial Registry (ChiCTR2100048947 DATE: 2021-07-19).</p><p><strong>Results: </strong>Ten gastric cancer patients with peritoneal metastasis were enrolled in two arms (four in Arm A and six in Arm B) from August 19th, 2021 to June 1st, 2022. Until the end of the follow-up date, the mPFS for Arm A was 5.70 m (95% CI: 1.29-10.11), while Arm B had a mPFS of 9.07 m (95% CI: 3.79-14.35). The mOS for Arm A and Arm B was 8.43 (95% CI: 6.70-10.17) and 11.23 months (95% CI: 2.90-19.56). At least one common Grade 3/4 AE occurred in 25% of Arm A participants and 16.7% of Arm B patients.</p><p><strong>Conclusions: </strong>Albumin-bound paclitaxel plus S-1 with a PD-1 inhibitor and intraperitoneal or intravenous bevacizumab was well tolerated in gastric cancer patients with peritoneal metastasis.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1010"},"PeriodicalIF":3.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}